Search

Pariglasgene Brecaparvovec-opnr (Genglycos; Ultragenyx Pharmaceutical Inc.) for Glycogen Storage Disease Type Ia

A gene therapy indicated to reduce daily cornstarch intake as an adjunct to nutritional management in adult and pediatric patients 8 years of age and older with glycogen storage disease type Ia.

Complete this form to request the full report